Open AccessBioVersys Works to Bring Antibiotic Resistance to an End
Author(s) -
Marcel Tigges,
Marc Gitzinger
Publication year - 2014
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2014.888
Subject(s) - resistance (ecology) , order (exchange) , work (physics) , engineering ethics , management , sociology , public relations , engineering , political science , business , biology , mechanical engineering , economics , ecology , finance
BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to overcome antibiotic resistance. The co-founders share their view on what makes successful scientists pursue a career as start-up entrepreneurs rather than a classic academic career. They describe the history and milestones of their company, and how their everyday work differs from that of peers in an academic or industrial research setting.